Biosimilars show comparable safety with Humira among new users with psoriasis in a multinational cohort study, but discontinuations were higher among those who switched from Humira to a biosimilar.

This trial compared the efficacy and safety of biosimilar cetuximab versus innovator cetuximab (IC) in combination with platinum-based chemotherapy in patients with recurrent locoregional or ...

China’s National Medical Products Administration authorized the country’s first cetuximab biosimilar with the approval of Simcere Zaiming’s Enlituo (CMAB-009, cetuximab beta injection) in combination ...

Metastatic squamous cell carcinoma of the head and neck carries a poor prognosis, but does cetuximab offer clinical benefits beyond those of platinum-based therapies?

Kashiv BioSciences has reported encouraging topline outcomes from the randomised confirmatory trial of the proposed biosimilar to Novartis’ Xolair (omalizumab), ADL-018.

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6.

A phase II clinical trial led by the Alliance for Clinical Trials in Oncology has met its primary endpoint, demonstrating that the combination of avelumab and cetuximab improved progression-free ...

The standard treatment for head and neck cancer, cisplatin, can’t be given to some patients due to pre-existing conditions. A new study compares the efficacy of two alternatives: cetuximab ...

SEOUL, March 10 (Yonhap) -- Celltrion Inc., a major South Korean biopharmaceutical firm, said Monday its biosimilar for asthma and other chronic allergic diseases has obtained approval for U.S. sales.

CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has been the most established biosimilar treatment in the Canadian ...